Mainstay of Treatment for Myeloma, Dexamethasone, Shows Very Significant Survival Benefit for COVID-19 Patients

Published Jun 16, 2020

Mainstay of Treatment for Myeloma, Dexamethasone, Shows Very Significant Survival Benefit for COVID-19 Patients

NOW
PLAYING
AML Stem-Cell Transplants: What You Need to Know Before, During, and After
NOW
PLAYING
CAR T Cell Therapy Reeducates Immune System for People With Certain Types of Blood Cancer
NOW
PLAYING
Nearly 40% of Clinical Trials Disrupted By COVID-19 Are Restarting; Guidance for Cancer Patients
NOW
PLAYING
I Have Cancer & Live in a COVID-19 Hotspot—What Should I Do?
NOW
PLAYING
Ovarian Cancer Clinical Trials
NOW
PLAYING
Adding Sarclisa to Treatment-- A Promising New Option for Relapsed Multiple Myeloma
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.